Regenexx Scores Yet Another Patent

At Regenexx we innovate. That’s what we’ve been doing for 15 years. Because of that innovation, this past week the USPTO awarded us yet another patent.

Regenexx 15 Years

You may have noticed that our logo changed this year. Why? Because we’ve been at this for 15 years. Think about that for a second. In an industry where people who have been doing this for a few years believe they have a great deal of experience, we’ve been at it for a decade and a half! That means we began using stem cells to treat orthopedic problems long before most everyone knew what that was.

Learn More About Regenexx^® Procedures

Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.

Your Email *

Include the weekly newsletter. It's free and you can unsubscribe at any time.

Submit

We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.

Our Patents

At this point, we hold so many patents that I’ve lost track. In addition, the main US patents then get registered into various countries around the world. So by the time that’s done, the number gets bigger and bigger.

Most of our patents are on lab processing. We do things VERY differently and this results in higher concentration orthobiologics with more platelets or stem cells. So that’s generated quite a few. Then we also have several device patents.

Our Best Looking Patent?

Check out this very cool Regenexx patent from Japan. While the American Patent above screams of the rugged individualism of the wild west, the Japanese patent speaks to that country’s love of the natural world. The Phoenix is believed to represent the rebirth of the Japanese nation after WWII.

What Was This Most Recent Patent About?

One of the reasons that we don’t use bedside machines to process cells and instead use a flexible lab platform is that processing things like blood, bone marrow, or fat can’t be done as well by existing machines. They all leave parts of the tissue out that have valuable cells. This patent focuses on bone marrow processing and that we discovered that all existing bedside machines were discarding valuable stem cells. At Regenexx, we don’t make that mistake.

The upshot? Regenexx has been at this a very long time. That speaks to the quality differences that separates what we do from most everyone else claiming to use platelets or stem cells. In addition, we continuously innovate and the fact that the USPTO and International Governments keep awarding us Patents speaks to that innovation.

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile